Clinical trial Recruiting at 1 site Observational Ages 18 and up

Tech-assisted upper limb rehabilitation after stroke

Official title: Effects of Using Advanced NEUROrehabilitation TECHnologies in Upper Limb Motor Function and Capacity Recovery in People With Stroke

Run by Azienda Unita Sanitaria Locale di Piacenza · NCT07698405 · Data updated 2026-11-12

A single-group study will test a personalized, technology-based upper limb rehab program added to usual therapy for adults with stroke.

More Stroke trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment25 (estimated)
SponsorAzienda Unita Sanitaria Locale di Piacenza
Academic / other
Locations1 site (Fiorenzuola d'Arda, Piacenza)
StatusRecruiting
StartedJune 15, 2026
Main results expectedAugust 2027
Study endsAugust 2027
Registry record updatedSeptember 22, 2026
Trial IDNCT07698405 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18+ with unilateral stroke and upper limb impairment, able to participate in intensive rehab, and with adequate cognitive function.

Probably not a fit

Patients with severe aphasia, bilateral brain lesions, unstable medical conditions, or other neurological/psychiatric disorders may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, single-cohort study enrolls adults with recent or past stroke who have upper limb impairment. Participants receive a 12- to 15-session, technology-assisted rehabilitation program three times per week, with each session lasting about one hour, in addition to conventional therapy. Researchers measure upper limb function with standard tests (FMA-UE and ARAT) and secondary outcomes like range of motion and grip strength over a 4–5 week period. The goal is to see how well this personalized, tech-enabled approach improves motor function and daily ability after stroke.

Why it matters

Potential benefit: If successful, participants may experience improvements in upper limb function and daily activities.

How similar studies have gone: Tech-based rehabilitation approaches such as robotics and virtual reality have shown positive effects on upper limb recovery in stroke in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years;
* First-ever unilateral ischemic or hemorrhagic stroke;
* Presence of upper limb motor impairment;
* Modified Ashworth Scale (MAS) \< 3;
* Montreal Cognitive Assessment (MoCA) \> 24;
* Medically stable and able to participate in an intensive rehabilitation programme;
* Ability to understand and follow study procedures;
* Written informed consent.

Exclusion Criteria:

* Diagnosis of severe aphasia, based on medical records, preventing participation;
* Bilateral hemisphere lesions;
* Severe and unstable medical conditions (e.g. untreated seizure, heart failure) that preclude participation in rehabilitation;
* Other neurological and/or psychiatric diseases;
* Recent and unstabilized upper limb fracture.

Where it's running

  • Fiorenzuola d'Arda Hospital - AUSL Piacenza
    Fiorenzuola d'Arda, Piacenza, Italy
    Recruiting

Study contacts

  • Principal investigator: Gianfranco Lamberti, MD — Azienda Unita Sanitaria Locale di Piacenza
  • Study coordinator: Gianfranco Lamberti, MD
  • Email: g.lamberti2@ausl.pc.it
  • Phone: +39 0523 404656

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.